RepliCel was founded to advance the breakthrough findings of Dr. Kevin McElwee and Dr. Rolf Hoffmann, established research scientists in the fields of immunology, hair biology, hair growth, and dermatology. In the early 2000s, at Phillips University in Marburg, Germany, these doctors discovered that dermal sheath cup cells have the ability to initiate cellular growth of mature hair follicles in animals.
The scientists’ landmark study titled,"Cultured Peribulbar Dermal Sheath Cells Can Induce Hair Follicle Development and Contribute to the Dermal Sheath and Dermal Papilla," was published in the peer-reviewed Journal of Investigative Dermatology in 2003 and forms the basis of both the RepliCel™ technology and the patent filings.
RepliCel is now developing this discovery as a potential successful treatment for hair loss in humans.In addition to the discovery of the critical cell population believed to be responsible for hair follicle growth, RepliCel has created a proprietary method for extracting and replicating these cells, with the goal of developing a safe, minimally invasive procedure for inducing natural hair growth in men and women suffering from various types of hair loss.
The RepliCel™ procedure has shown significant promise in standard pre-clinical animal trials. The procedure is now undergoing rigorous human studies to establish safety and determine effectiveness. RepliCel began their first human clinical trial (Phase I/IIa) in the country of Georgia in December 2010. To date, there have been no adverse effects reported.
Initial results from this clinical trial are expected to be released in April 2012. Data from this clinical trial will be used for the development of a Phase IIb dose-ranging clinical trial of 100 patients which is expected to commence in the fall of 2012 in Europe and/or North America.
Patents for the technology are now issued in the Europe Union and Australia and are pending in the US, Canada, and Japan.
What They Do: The Company has developed RepliCel™, a natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women.
Codexis (Nasdaq: CDXS) $3.76. Announced Tuesday after market close that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia®. “FDA approval of this manufacturing process is a major milestone for Codexis,” said Peter Strumph, Interim Chief Executive Officer. “This is another example of how our directed evolution technology can deliver well controlled, cost advantaged commercial pharmaceutical, biofuel, or bio-based chemical production processes.”
The approved process, which won the Presidential Green Chemistry Award in 2010, is a more environmentally friendly and efficient production process than those used in the past. Specifically, it indicates the potential for improving the overall increase in yield of sitagliptin, while significantly decreasing waste byproducts.
What They Do: Codexis, Inc. is a developer of industrial enzymes to enable the production of biofuels, biobased chemicals and pharmaceutical intermediates.
Halcón Resources Corporation and GeoResources, Inc. (Nasdaq: GEOI) $30.77. Today announced that they have entered into a definitive merger agreement in which GeoResources will merge into a wholly-owned subsidiary of Halcón Resources in a cash and stock transaction that values GeoResources at approximately $1.0 billion, based on the closing price of Halcón Resources common stock on April 24, 2012. Under the terms of the merger agreement, Halcón Resources will acquire all outstanding shares of GeoResources common stock. GeoResources stockholders will receive $20.00 in cash and 1.932 shares of Halcón Resources common stock for each share of GeoResources common stock they hold, representing consideration to GeoResources stockholders of $37.97 per share based on the closing price of Halcón Resources common stock on April 24, 2012.
Halcón Resources Corporation will continue to be led by Floyd C. Wilson, Halcón Resources’ Chairman, President and Chief Executive Officer and Mark J. Mize, Executive Vice President, Chief Financial Officer and Treasurer. Upon completion of the merger, the stockholders of GeoResources are expected to own approximately 18% of the combined company’s outstanding shares on a fully diluted basis.
What They Do: GeoResources, Inc. is an independent oil and gas company engaged in the development and acquisition of oil and gas reserves through an active and diversified program that includes the acquisition, drilling and development of undeveloped leases, purchases of reserves and exploration activities, currently focused in the Southwest, Gulf Coast, and the Williston Basin.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has been compensated three thousand five hundred dollars by a third party New Millennium for its services with regards to Replicel Sciences.
SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play.